Daniel Zielonka

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

J.-M. Lee, E.M. Ramos, J.-H. Lee et al. · Neurology · 2012 · 391 citations · Full text

Life Sciences, Genetics, Neurology +15

The influence of gender on phenotype and disease progression in patients with Huntington's disease

Daniel Zielonka, Johan Marinus, Raymund A.C. Roos et al. · Parkinsonism & Related Disorders · 2012 · 115 citations

Life Sciences, Neurology, Neuroscience +9

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

Ralf Reilmann, Andrew McGarry, Igor D. Grachev et al. · The Lancet Neurology · 2018 · 108 citations

Medicine, Neurology, Pharmacology +10

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis

Patrick Vermersch, Luís Brieva, Robert J. Fox et al. · Neurology Neuroimmunology & Neuroinflammation · 2022 · 67 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease

Daniel Zielonka, Michał Ren, Giuseppe De Michele et al. · Parkinsonism & Related Disorders · 2018 · 57 citations

Medicine, Neurology, Neuroscience +12